BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 8478667)

  • 1. Phase I and plasma pharmacokinetic study of infusional fluorouracil combined with recombinant interferon alfa-2b in patients with advanced cancer.
    Danhauser LL; Freimann JH; Gilchrist TL; Gutterman JU; Hunter CY; Yeomans AC; Markowitz AB
    J Clin Oncol; 1993 Apr; 11(4):751-61. PubMed ID: 8478667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A pilot study of interferon alfa-2a in combination with fluorouracil plus high-dose leucovorin in metastatic gastrointestinal carcinoma.
    Grem JL; McAtee N; Murphy RF; Balis FM; Steinberg SM; Hamilton JM; Sorensen JM; Sartor O; Kramer BS; Goldstein LJ
    J Clin Oncol; 1991 Oct; 9(10):1811-20. PubMed ID: 1919632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I trial of 5-fluorouracil and dipyridamole administered by seventy-two-hour concurrent continuous infusion.
    Remick SC; Grem JL; Fischer PH; Tutsch KD; Alberti DB; Nieting LM; Tombes MB; Bruggink J; Willson JK; Trump DL
    Cancer Res; 1990 May; 50(9):2667-72. PubMed ID: 2328492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I trial of 5-fluorouracil and recombinant alpha 2a-interferon in patients with advanced colorectal carcinoma.
    Wadler S; Goldman M; Lyver A; Wiernik PH
    Cancer Res; 1990 Apr; 50(7):2056-9. PubMed ID: 2317795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I trial of interferon alpha-2b with folinic acid and 5-fluorouracil administered by 4-hour infusion in metastatic colorectal carcinoma.
    Kreuser ED; Hilgenfeld RU; Matthias M; Hoksch B; Boewer C; Oldenkott B; Knauf WU; Boese-Landgraf J; Schalhorn A; Zeitz M
    Semin Oncol; 1992 Apr; 19(2 Suppl 3):197-203. PubMed ID: 1557647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II trial of hepatic arterial infusion of fluorouracil and recombinant human interferon alfa-2b for liver metastases of colorectal cancer refractory to systemic fluorouracil and leucovorin.
    Patt YZ; Hoque A; Lozano R; Pozdur R; Chase J; Carrasco H; Chuang V; Delpassand ES; Ellis L; Curley S; Roh M; Jones DV
    J Clin Oncol; 1997 Apr; 15(4):1432-8. PubMed ID: 9193336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I trial of 5-fluorouracil, leucovorin, and dipyridamole given by concurrent 120-h continuous infusions.
    Bailey H; Wilding G; Tutsch KD; Arzoomanian RZ; Alberti D; Tombes MB; Grem JL; Spriggs DR
    Cancer Chemother Pharmacol; 1992; 30(4):297-302. PubMed ID: 1643698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I evaluation of therapy with four schedules of 5-fluorouracil by continuous infusion combined with recombinant interferon alpha.
    Greenblatt MS; Mangalik A; Ferguson J; Elias L
    Clin Cancer Res; 1995 Jun; 1(6):615-20. PubMed ID: 9816023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase IA trial of sequential administration recombinant DNA-produced interferons: combination recombinant interferon gamma and recombinant interferon alfa in patients with metastatic renal cell carcinoma.
    Ernstoff MS; Nair S; Bahnson RR; Miketic LM; Banner B; Gooding W; Day R; Whiteside T; Hakala T; Kirkwood JM
    J Clin Oncol; 1990 Oct; 8(10):1637-49. PubMed ID: 2120392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma and tumor tissue pharmacology of high-dose intravenous leucovorin calcium in combination with fluorouracil in patients with advanced colorectal carcinoma.
    Trave F; Rustum YM; Petrelli NJ; Herrera L; Mittelman A; Frank C; Creaven PJ
    J Clin Oncol; 1988 Jul; 6(7):1184-91. PubMed ID: 3260621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I trial of low-dose, prolonged continuous infusion fluorouracil plus interferon-alfa: evidence for enhanced fluorouracil toxicity without pharmacokinetic perturbation.
    Sparano JA; Wadler S; Diasio RB; Zhang R; Lu Z; Schwartz EL; Einzig A; Wiernik PH
    J Clin Oncol; 1993 Aug; 11(8):1609-17. PubMed ID: 8336197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I-phase II trial of N-phosphonacetyl-L-aspartic acid given by intravenous infusion and 5-fluorouracil given by bolus injection.
    Erlichman C; Donehower RC; Speyer JL; Klecker R; Chabner BA
    J Natl Cancer Inst; 1982 Feb; 68(2):227-31. PubMed ID: 6950156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study.
    Chabot GG; Armand JP; Terret C; de Forni M; Abigerges D; Winograd B; Igwemezie L; Schacter L; Kaul S; Ropers J; Bonnay M
    J Clin Oncol; 1996 Jul; 14(7):2020-30. PubMed ID: 8683232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cisplatin, fluorouracil, and leucovorin augmented by interferon alfa-2b in head and neck cancer: a clinical and pharmacologic analysis.
    Vokes EE; Ratain MJ; Mick R; McEvilly JM; Haraf D; Kozloff M; Hamasaki V; Weichselbaum RR; Panje WR; Wenig B
    J Clin Oncol; 1993 Feb; 11(2):360-8. PubMed ID: 8426214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of effect of interferon alpha 2a upon fluorouracil pharmacokinetics.
    Seymour MT; Patel N; Johnston A; Joel SP; Slevin ML
    Br J Cancer; 1994 Oct; 70(4):724-8. PubMed ID: 7917928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II trial of intravenous flourouracil and subcutaneous interferon alfa-2b for biliary tract cancer.
    Patt YZ; Jones DV; Hoque A; Lozano R; Markowitz A; Raijman I; Lynch P; Charnsangavej C
    J Clin Oncol; 1996 Aug; 14(8):2311-5. PubMed ID: 8708722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of 5-fluorouracil and recombinant interferon alpha-2B in advanced gastric cancer. A phase I study.
    Lee KH; Lee JS; Suh C; Lee YS; Min YI; Ahn SH; Park KC; Kim SK; Kim SH
    Am J Clin Oncol; 1992 Apr; 15(2):141-5. PubMed ID: 1553902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I and pharmacologic study of PN401 and fluorouracil in patients with advanced solid malignancies.
    Hidalgo M; Villalona-Calero MA; Eckhardt SG; Drengler RL; Rodriguez G; Hammond LA; Diab SG; Weiss G; Garner AM; Campbell E; Davidson K; Louie A; O'Neil JD; von Borstel R; Von Hoff DD; Rowinsky EK
    J Clin Oncol; 2000 Jan; 18(1):167-77. PubMed ID: 10623707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatic and serologic toxicity of systemic interleukin-2 and/or interferon-alpha. Evidence of a risk-benefit advantage of subcutaneous therapy.
    Schomburg A; Kirchner H; Lopez-Hänninen E; Menzel T; Rudolph P; Körfer A; Fenner M; Poliwoda H; Atzpodien J
    Am J Clin Oncol; 1994 Jun; 17(3):199-209. PubMed ID: 7910716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Locus of the interaction among 5-fluorouracil, leucovorin, and interferon-alpha 2a in colon carcinoma cells.
    Houghton JA; Morton CL; Adkins DA; Rahman A
    Cancer Res; 1993 Sep; 53(18):4243-50. PubMed ID: 8364921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.